Circio
Circio Holding ASA is a biotechnology company developing novel circular RNA and immunotherapy medicines. Circio has established a unique circular RNA (circRNA) platform to develop novel circRNA medicines for rare disease, vaccines and cancer. The proprietary circVec technology is based on a modular genetic cassette design for efficient biogenesis of multifunctional circRNA from DNA and viral vectors, which can be deployed for many purposes.
Latest Circio Content
Product News
Circio Announces Strengthened In Vivo Data and Enhanced circVec 2.2 Design
circVec 2.1 DNA vectors have now demonstrated higher and more durable expression vs. conventional mRNA-based expression in vivo for up to five months.
Product News
Circio Presents Pre-Clinical Proof-of-Concept Data for Its circVec Gene Therapy Platform at the ASGCT 2024 Meeting
Two posters demonstrate in vivo superiority of circular RNA vs. linear mRNA-based expression and technical proof-of-concept for Circio´s ´remove-&-replace´ gene therapy format for the unmet medical need AATD.
Industry Insight
Harnessing the Therapeutic Potential of Circular RNA
In this interview, Erik Digman Wiklund tells us about the discovery of circRNA and discusses some of the challenges of harnessing its full potential for therapeutic interventions.
Advertisement
